Dominik Schulz1, Markus Wirth2, Guido Piontek3, Andreas Knopf3, Christoph Straube4,5, Steffi Pigorsch4,5, Stephanie E Combs4,5,6, Anja Pickhard3. 1. Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 2. Department of Otolaryngology Head and Neck Surgery, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. markus.wirth@tum.de. 3. Department of Otolaryngology Head and Neck Surgery, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. 4. Department of Radiation Oncology and Radiotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 5. Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany. 6. Department of Radiation Sciences (DRS), Institute for Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Abstract
PURPOSE: While metastases directed therapy for oligometastatic disease is recommended in different cancer entities, the treatment of solitary metastases in head and neck squamous cell carcinoma (HNSCC) patients is not clearly defined. METHODS: A retrospective analysis was performed on data from 143 HNSCC patients treated between 2001 and 2016 in a tertiary university hospital. Clinical factors and outcome were measured using the median survival of patients receiving metastases specific therapy in comparison with matched control patients. RESULTS: In 37 patients, distant metastases were treated specifically with either surgery and/or stereotactic ablative radiotherapy and had with 23.97 months a more than three times higher median survival than 10 untreated matched controls with potentially treatable distant metastases (7.07 months). CONCLUSIONS: Our retrospective analysis demonstrates a significant survival benefit for HNSCC patients who received a specific therapy regarding distant metastasis irrespective of localization as compared to a matched control cohort.
PURPOSE: While metastases directed therapy for oligometastatic disease is recommended in different cancer entities, the treatment of solitary metastases in head and neck squamous cell carcinoma (HNSCC) patients is not clearly defined. METHODS: A retrospective analysis was performed on data from 143 HNSCCpatients treated between 2001 and 2016 in a tertiary university hospital. Clinical factors and outcome were measured using the median survival of patients receiving metastases specific therapy in comparison with matched control patients. RESULTS: In 37 patients, distant metastases were treated specifically with either surgery and/or stereotactic ablative radiotherapy and had with 23.97 months a more than three times higher median survival than 10 untreated matched controls with potentially treatable distant metastases (7.07 months). CONCLUSIONS: Our retrospective analysis demonstrates a significant survival benefit for HNSCCpatients who received a specific therapy regarding distant metastasis irrespective of localization as compared to a matched control cohort.
Entities:
Keywords:
Distant metastases; HNSCC; Overall survival; Radiotherapy; Specific treatment
Authors: Ken-Ryu Han; Allan J Pantuck; Matthew H T Bui; Oleg Shvarts; Danielo G Freitas; Amnon Zisman; Bradley C Leibovich; Frederick J Dorey; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun Journal: Urology Date: 2003-02 Impact factor: 2.649
Authors: Steven Borson; Yongli Shuai; Barton F Branstetter; Marci Lee Nilsen; Marion A Hughes; Moon Fenton; Mark Kubik; Shaum Sridharan; David A Clump; Heath D Skinner; Jonas T Johnson; Simion I Chiosea; James Ohr; Umamaheswar Duvvuri; Seungwon Kim; Katie S Traylor; Robert Ferris; Dan P Zandberg Journal: Laryngoscope Investig Otolaryngol Date: 2022-05-06
Authors: Thomas Weissmann; Daniel Höfler; Markus Hecht; Sabine Semrau; Marlen Haderlein; Irina Filimonova; Benjamin Frey; Christoph Bert; Sebastian Lettmaier; Konstantinos Mantsopoulos; Heinrich Iro; Rainer Fietkau; Florian Putz Journal: Radiat Oncol Date: 2021-03-31 Impact factor: 3.481
Authors: J Engstrand; L F Abreu de Carvalho; D Aghayan; A Balakrishnan; A Belli; B Björnsson; B V M Dasari; O Detry; M Di Martino; B Edwin; J Erdmann; R Fristedt; G Fusai; T Gimenez-Maurel; O Hemmingsson; C Hidalgo Salinas; B Isaksson; A Ivanecz; F Izzo; W T Knoefel; P Kron; N Lehwald-Tywuschik; M Lesurtel; J P A Lodge; N Machairas; M V Marino; V Martin; A Paterson; J Rystedt; P Sandström; A Serrablo; A K Siriwardena; H Taflin; T M van Gulik; S Yaqub; I Özden; J M Ramia; C Sturesson Journal: BJS Open Date: 2021-07-06
Authors: Ciro Franzese; M Badalamenti; A Teriaca; A De Virgilio; G Mercante; R Cavina; D Ferrari; A Santoro; G Spriano; M Scorsetti Journal: J Cancer Res Clin Oncol Date: 2021-01-20 Impact factor: 4.553
Authors: Craig A Bollig; Christopher I Newberry; Tabitha L I Galloway; Robert P Zitsch; Elyse K Hanly; Vivian L Zhu; Nitin Pagedar; Rohit Nallani; Andres M Bur; William C Spanos; Jeffrey B Jorgensen Journal: Laryngoscope Date: 2020-10-24 Impact factor: 3.325